论文部分内容阅读
目的：观察ＢＡＬＢ／Ｃ小鼠脾来源树突状细胞（ｓｐｌｅｅｎｄｅｎｄｒｉｔｉｃｃｅｌｓ，ｓＤＣ）与肿瘤细胞融合体的抗肿瘤效应。方法：以灭活的ＮＳ１细胞免疫活化ＢＡＬＢ／Ｃ小鼠，取其ｓＤＣ与ＮＳ１骨髓瘤细胞融合，并筛选出融合细胞；用此融合细胞作为瘤苗，免疫治疗皮下荷ＮＳ１瘤的小鼠２次，间隔１周。结果：融合细胞瘤苗本身无致瘤性。用融合细胞瘤苗免疫治疗荷瘤小鼠后，其瘤体消失，且在观察期６０ｄ内未见肿瘤转移和复发。结论：脾来源树突状细胞与ＮＳ１细胞融合瘤苗免疫荷瘤小鼠后，激发其体内存在的抗ＮＳ１肿瘤效应。
OBJECTIVE: To observe the anti-tumor effects of fusions of spleen-derived dendritic cells (sDCs) and tumor cells in BALB/c mice. METHODS: BALB/C mice were immunoactivated with inactivated NS1 cells, sDCs were fused with NS1 myeloma cells, and fusion cells were selected; the fusion cells were used as tumor vaccines to immunotherapy subcutaneous NS1 tumor-bearing mice 2 Times, interval 1 week. Results: The fused cell tumor vaccine itself was not tumorigenic. After tumor-bearing mice were treated with fused cell tumor vaccine, their tumors disappeared and no tumor metastasis or recurrence occurred within 60 days of the observation period. CONCLUSION: The fusion of spleen-derived dendritic cells with NS1 cells in tumor-bearing mice immunized tumor-bearing mice and stimulated their anti-NS1 tumor effects in vivo.